Cibus Gestion

Gestion contrôle des critères 2/4

Le PDG Cibus est Rory Riggs, nommé en Jan2001, a un mandat de 23.83 ans. La rémunération annuelle totale est $ 292.31K, composée du salaire de 100% et des bonus 0%, y compris les actions et options de la société. détient directement 13.12% des actions de la société, d'une valeur de $ 15.40M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.1 ans et 1.4 ans.

Informations clés

Rory Riggs

Directeur général

US$292.3k

Rémunération totale

Pourcentage du salaire du PDG	100.0%
Durée du mandat du directeur général	23.8yrs
Propriété du PDG	13.1%
Durée moyenne d'occupation des postes de direction	5.1yrs
Durée moyenne du mandat des membres du conseil d'administration	1.4yrs

Mises à jour récentes de la gestion

Recent updates

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Oct 07

Calyxt exploring strategic alternatives

Sep 22

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Apr 01

Calyxt Needs To Secure More Commercial Partners As Cash Dwindles

Sep 16

Analyse de la rémunération des PDG

Comment la rémunération de Rory Riggs a-t-elle évolué par rapport aux bénéfices de Cibus?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$445m
Jun 30 2024	n/a	n/a	-US$292m
Mar 31 2024	n/a	n/a	-US$286m
Dec 31 2023	US$292k	US$292k	-US$268m

Rémunération vs marché: La rémunération totale de Rory ($USD 292.31K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 652.28K ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Rory avec les performances de l'entreprise.

PDG

Rory Riggs (71 yo)

23.8yrs

Titularisation

US$292,314

Compensation

Mr. Rory Balfour Riggs, MBA, serves as Chief Executive Officer of Cibus, Ltd. since October 2021. He is Co-Founder at Cibus, Inc. and is its Chief Executive Officer and Chairman since June 1, 2023.Mr. Rig...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Rory Riggs	Co-Founder	23.8yrs	US$292.31k	13.12% $ 15.4m
Peter Beetham	Co-Founder	1.4yrs	US$292.31k	0.29% $ 336.3k
Greg Gocal	Co-Founder	8.8yrs	US$266.01k	0.24% $ 279.4k
Jason Stokes	Chief Legal Officer	less than a year	pas de données	pas de données
Rosa Kim	Senior Vice President of Legal	no data	pas de données	pas de données
James Radtke	Senior Vice President of Product Development	no data	pas de données	pas de données
Tony Moran	Senior Vice President of International Development	no data	pas de données	pas de données
Norm Sissons	Senior Vice President of Seed & Traits	no data	pas de données	pas de données
Noel Sauer	Senior Vice President of Research	no data	pas de données	pas de données
Sean O'Connor	Senior VP and President & CEO of Nucelis	no data	pas de données	pas de données

5.1yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de CBUS est chevronnée et expérimentée (5.1 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Rory Riggs	Co-Founder	1.4yrs	US$292.31k	13.12% $ 15.4m
Peter Beetham	Co-Founder	1.4yrs	US$292.31k	0.29% $ 336.3k
Gerhard Prante	Independent Vice Chairman	1.4yrs	pas de données	0.27% $ 318.5k
Mark Finn	Lead Independent Director	1.4yrs	pas de données	0.25% $ 289.4k
Keith Walker	Independent Director	1.4yrs	pas de données	0.32% $ 373.5k
Joseph Ecker	Member of Scientific Advisory Board	no data	pas de données	pas de données
Jean-Pierre Lehmann	Independent Director	1.4yrs	pas de données	6.65% $ 7.8m
Jan Leach	Member of Scientific Advisory Board	no data	pas de données	pas de données
Stephen Howell	Member of Scientific Advisory Board	no data	pas de données	pas de données
Richard Meagher	Member of Scientific Advisory Board	no data	pas de données	pas de données

1.4yrs

Durée moyenne de l'emploi

78yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la CBUS n'est pas considéré comme expérimenté ( 1.4 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

Cibus Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Cibus, Inc. Announces CFO Changes, Effective September 30, 2024

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc., Annual General Meeting, May 30, 2024

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Cibus, Inc. Appoints Jim Collins to Board of Directors

Recent updates

Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance in Canola

Consensus revenue estimates increase by 71%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2024

Cibus, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

New major risk - Share price stability

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cibus, Inc. Announces CFO Changes, Effective September 30, 2024

Consensus EPS estimates fall by 12%

Price target decreased by 10% to US$19.75

New major risk - Financial position

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cibus, Inc. Expands Its Intellectual Property Coverage for Plant Gene Editing and Traits

New minor risk - Share price stability

Cibus’ White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola

Full year 2023 earnings released: US$25.95 loss per share (vs US$18.36 loss in FY 2022)

Consensus revenue estimates increase by 18%

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc. to Report Q1, 2024 Results on May 09, 2024

Cibus, Inc., Annual General Meeting, May 30, 2024

Consensus EPS estimates upgraded to US$3.03 loss, revenue downgraded

Consensus EPS estimates fall by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales

Cibus: Expanding Opportunities And Growing Accessible Market

Cibus, Inc. Announces Successfully Regenerated Plants from Single Cells in Wheat

Cibus, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 13% to US$22.00

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Is Cibus, Inc. (NASDAQ:CBUS) Trading At A 44% Discount?

Cibus, Inc. Appoints Jim Collins to Board of Directors

Does Cibus (NASDAQ:CBUS) Have A Healthy Balance Sheet?

Consensus revenue estimates fall by 60%

Second quarter 2023 earnings released: US$3.05 loss per share (vs US$2.66 loss in 2Q 2022)

Cibus, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target decreased by 50% to US$18.00

Consensus revenue estimates increase by 46%

New major risk - Shareholder dilution

First quarter 2023 earnings released: US$1.09 loss per share (vs US$1.34 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Calyxt, Inc. Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

Calyxt Gets 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 3Q 2021)

Calyxt, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Calyxt, Inc Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Calyxt exploring strategic alternatives

Consensus forecasts updated

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$0.053 loss per share (vs US$0.13 loss in 2Q 2021)

Price target increased to US$6.83

Calyxt, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Calyxt Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$4.99

High number of new directors

Calyxt, Inc. Announces Directorate Appointments

Calyxt, Inc. to Report Q1, 2022 Results on May 05, 2022